Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(CHRONO-RCC) Time-of-day-Dependent Administration of Dual Immune Check Point Inhibitors (ICI) in Advanced Kidney Cancer

NCT07338981 is registered in ClinicalTrials.gov with Guliz Ozgun as lead sponsor.

NCT NCT07338981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07338981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(CHRONO-RCC) Time-of-day-Dependent Administration of Dual Immune Check Point Inhibitors (ICI) in Advanced Kidney Cancer
Lead sponsor
Guliz Ozgun
Phase
Phase 3
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
December 31, 2033
Enrollment
142 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced kidney cancer